Immatics (IMTX) EBITDA (2019 - 2025)
Immatics (IMTX) posted EBITDA of -$417891.6 for Q4 2025, up 99.3% sequentially from -$59.6 million in Q3 2025, and down 100.91% YoY from $46.0 million in Q4 2024.
Immatics (IMTX) EBITDA (2019 - 2025) Analysis & Trends
Immatics has reported EBITDA for 7 years, with the latest figure at -$417891.6 in Q4 2025.
- Quarterly EBITDA fell 100.91% year-over-year to -$417891.6 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$172.0 million (down 2228.55% YoY) and the FY2025 annual result came in at -$205.6 million, down 392.04% from the prior year.
- EBITDA advanced to -$417891.6 in Q4 2025 per IMTX's latest filing, from -$59.6 million in the prior quarter.
- Over five years, EBITDA peaked at $94.9 million in Q1 2022 and troughed at -$59.6 million in Q3 2025.
- A 5-year average of -$16.9 million and a median of -$20.6 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA surged 427.26% in 2022, then tumbled 2086.97% in 2025.
- Over 5 years, EBITDA stood at -$19.6 million in 2021, then increased by 12.75% to -$17.1 million in 2022, then slipped by 18.97% to -$20.3 million in 2023, then jumped by 326.32% to $46.0 million in 2024, then plunged by 100.91% to -$417891.6 in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$417891.6, -$59.6 million, and -$55.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | -45.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -417,891.62 |
| Sep 30, 2025 | -59.58 Mn |
| Jun 30, 2025 | -54.98 Mn |
| Mar 31, 2025 | -57.00 Mn |
| Dec 31, 2024 | 45.99 Mn |
| Sep 30, 2024 | -16.41 Mn |
| Jun 30, 2024 | -18.90 Mn |
| Mar 31, 2024 | -2.61 Mn |
| Dec 31, 2023 | -20.32 Mn |
| Sep 30, 2023 | -30.55 Mn |
| Jun 30, 2023 | -28.04 Mn |
| Mar 31, 2023 | -24.96 Mn |
| Dec 31, 2022 | -17.08 Mn |
| Sep 30, 2022 | -20.98 Mn |
| Jun 30, 2022 | -13.26 Mn |
| Mar 31, 2022 | 94.89 Mn |
| Dec 31, 2021 | -19.58 Mn |
| Sep 30, 2021 | -32.28 Mn |
| Jun 30, 2021 | -32.71 Mn |
| Mar 31, 2021 | -28.99 Mn |